Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Palatin Technologies and King Pharmaceuticals have announced positive results from a clinical study evaluating the co-administration of PT-141 and Viagra in erectile dysfunction. Palatin shares have been boosted by more than 10% on the news.
Subscribe to our email newsletter
The purpose of the study was to evaluate the potential additive effect of treating erectile dysfunction (ED) patients with both PT-141, which initiates erections via a central nervous system mechanism of action, and Pfizer’s Viagra, a peripheral vasodilator indicated for erectile dysfunction.
Doses of either 50mg or 100mg Viagra were administered to 32 ED patients with or without PT-141 (7.5mg or 10mg). Each patient’s erectile activity was monitored for six hours using a RigiScan device.
The duration of erectile activity measured after co-administration of each combination of PT-141 was significantly enhanced compared to that observed with the relevant dose of Viagra alone.
Furthermore, co-administration of PT-141 and Viagra did not result in any serious or significant adverse events.
“The co-administration of PT- 141 and Viagra may constitute an important treatment alternative for ED patients in whom higher doses of a single therapy are not effective or are not well-tolerated,” said Dr Carl Spana, president and CEO of Palatin. “Additionally, the results of this study support the proposed mechanism of action for PT-141.”